有机化学人才网 | 最新人才 | 最新职位 | 技术交易 | 药物合成 |
   
全站搜索: |
  您当前位置:网站首页 >> 药物合成路线图解
 

药物详细合成路线

Name Everolimus;RAD-001;NVP-RAD-001;SDZ-RAD;Certican
Chemical Name [1R,9S,12S[1R(1S,3R,4R)],15R,18R,19R,21R,23S,30S,32S,35R]-1,18-Dihydroxy-12-[2-[4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16(E),24(E),26(E),28(E)-tetraene-2,3,10,14,20-pentaone
      40-O-(2-Hydroxyethyl)rapamycin
      (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1(R)-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentaone
CAS 159351-69-6
Related CAS
Formula C53H83NO14
Structure
Formula Weight 958.25076
Stage 上市-2004
Company Novartis (Originator), Guidant (Licensee)
Activity/Mechanism Antiarthritic Drugs, CARDIOVASCULAR DRUGS, IMMUNOMODULATING AGENTS, Immunosuppressants, Oncolytic Drugs, Restenosis Treatment of, Rheumatoid Arthritis, Treatment of, Solid Tumors Therapy, Treatment of Disorders of the Coronary Arteries and Atherosclerosis, TREATMENT OF MUSCULOSKELETAL & CONNECTIVE TISSUE DISEASES, Treatment of Transplant Rejection, Inhibitors of Signal Transduction Pathways, mTOR Inhibitors, Rapamycins, Rotamase (FKBP12) Inhibitors
Syn. Route 4
Route 1
alkylation of rapamycin (i) with 2-(tert-butyldimethylsilyloxy)ethyl triflate (ii) by means of 2,6-lutidine in hot toluene gives the silylated target compound (iii), which is deprotected by means of 1n hcl in methanol.
List of intermediates No.
1-allyl-5-bromo-4-azepanone (i)
7-chloro-5-(2-chlorophenyl)-1-methyl-2-oxo-2,3-dihydro-1h-1,4-benzodiazepin-4-ium-4-olate (ii)
7-chloro-5-(2-chlorophenyl)-1-methyl-2-oxo-2,3-dihydro-1h-1,4-benzodiazepin-3-yl acetate (iii)
Reference 1:
    casta?er, j.; sorbera, l.a.; leeson, p.a.; sdz-rad. drugs fut 1999, 24, 1, 22.
Reference 2:
    cottens, s.; sedrani, r. (novartis ag; novartis deutschland gmbh); o-alkylated rapamycin derivs. and their use, particularly as immunosuppressants. ep 0663916; ep 0867438; jp 1996502266; jp 1999240884; us 5665772; wo 9409010 .

Route 2
the compound has been obtained biosynthetically by an optimized fermentation process using streptomyces hygroscopicus mutant rsh 1701 with a complex culture medium were [14c]-labeled (1r,3r,4r)-2,3-dichydroxycyclo-hexanecarboxylic acid (i) and [14c]-labeled (s)-pipecolic acid (ii) have been added. this fermentation process yielded [14c]-labeled rapamycin (iii), which was finally selectively o-alkylated at the c-40 position with monosilylated ethylene glycol triflate in dmso/dimethoxyethane.
List of intermediates No.
(1s,2s)-3-amino-1-(2-ethoxyphenoxy)-1-phenyl-2-propanol (ii)
1-allyl-5-bromo-4-azepanone (iii)
(1s,3z,8s,9s,10r,11r)-9-(benzyloxy)-11-[[tert-butyl(dimethyl)silyl]oxy]-8,10,12,12-tetramethyl-1-[(e)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]-13-oxo-3-tridecenyl acetate (i)
{(2r,3r,5r)-3-(acetyloxy)-4-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl 2-(acetyloxy)-2-methylpropanoate (i)
{(2r,4s,5r)-4-(acetyloxy)-3-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl 2-(acetyloxy)-2-methylpropanoate (ii)
{(2r,3r,5r)-3-(acetyloxy)-4-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl acetate (iii)
Reference 1:
    moenius, t.; et al.; c-14 labelling of nvp rad001 - a new rapamycin derivative. j label compd radiopharm 1999, 42, 1, 29.

Route 3
the reaction of the labeled acylated (+)-bornane-10,2-sultam (iv) with triethyl phosphite gives the phosphonate (v), which is treated with paraformaldehyde, galvinoxyl and k2co3 yielding the acrylate derivative (vi). the cyclization of (vi) with butadiene (vii) by means of diethylaluminum chloride and galvinoxyl (as radical scavenger) affords the cyclohexene-carboxamide derivative (viii), which is hydrolyzed with lioh in thf/water giving the (1r)-3-cyclohexenecarboxylic acid (ix). the oxidation of (ix) with m-chloroperbenzoic acid and triethylamine in ccl4 yielded regioselectively the hydroxylactone (x), which is finally hydrolyzed with hcl to the labeled intermediate (i).
List of intermediates No.
4-hydroxy-1-indanone (x)
(2r)-2-([[(2s)-1-(tert-butoxycarbonyl)pyrrolidinyl]carbonyl]amino)propionic acid (vii)
(2r)-2-([[(2s)-1-((2s)-2-[(tert-butoxycarbonyl)amino]-6-[[(ethylamino)(ethylimino)methyl]amino]hexanoyl)pyrrolidinyl]carbonyl]amino)propionic acid (ix)
(1s,3z,8s,9s,10r,11r)-9-(benzyloxy)-11-[[tert-butyl(dimethyl)silyl]oxy]-8,10,12,12-tetramethyl-1-[(e)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]-13-oxo-3-tridecenyl acetate (i)
1-isopropoxyvinyl trimethylsilyl ether; [(1-isopropoxyvinyl)oxy](trimethyl)silane (iv)
isopropyl (3s,5r,6r,7s,8s,12z,15s,16e)-15-(acetoxy)-7-(benzyloxy)-5-[[tert-butyl(dimethyl)silyl]oxy]-3-hydroxy-4,4,6,8,16-pentamethyl-17-(2-methyl-1,3-thiazol-4-yl)-12,16-heptadecadienoate (v)
isopropyl (3s,5r,6s,7s,8s,12z,15s,16e)-15-(acetoxy)-7-(benzyloxy)-3,5-dihydroxy-4,4,6,8,16-pentamethyl-17-(2-methyl-1,3-thiazol-4-yl)-12,16-heptadecadienoate (vi)
isopropyl (3s,5r,6s,7s,8s,12z,15s,16e)-15-(acetoxy)-7-(benzyloxy)-3-[[tert-butyl(dimethyl)silyl]oxy]-5-hydroxy-4,4,6,8,16-pentamethyl-17-(2-methyl-1,3-thiazol-4-yl)-12,16-heptadecadienoate (viii)
{(2r,3r,5r)-3-(acetyloxy)-4-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl 2-(acetyloxy)-2-methylpropanoate (i)
{(2r,5r)-4-(acetyloxy)-3-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl acetate (iv)
{(2s,5r)-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]-2,5-dihydro-2-furanyl}methyl acetate (v)
{(2s,5r)-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]-2,5-dihydro-2-furanyl}methyl 2-(acetyloxy)-2-methylpropanoate (vi)
2-({(2s,5r)-5-[5-fluoro-2-oxo-4-(1h-1,2,4-triazol-1-yl)-1(2h)-pyrimidinyl]-2,5-dihydro-2-furanyl}methoxy)-1,1-dimethyl-2-propenyl acetate (viii)
2-({(2s,5r)-5-[4-amino-5-fluoro-2-oxo-1(2h)-pyrimidinyl]-2,5-dihydro-2-furanyl}methoxy)-1,1-dimethyl-2-propenyl acetate (ix)
1-(tert-butyl) 3-methyl 5,6-dihydro-1,3(2h)-pyridinedicarboxylate (x)
Reference 1:
    moenius, t.; et al.; c-14 labelling of nvp rad001 - a new rapamycin derivative. j label compd radiopharm 1999, 42, 1, 29.

Route 4
the reaction of the labeled acylated (-)-bornane-10,2-sultam (xi) with benzophenone imine (xii) gives the glycylsultam derivative (xiii), which is alkylated with 4-iodobutyl chloride (xiv) by means of butyllithium and dmpu in thf yielding intermediate (xv). the selective hydrolysis of (xv) with hcl affords the omega-chloro-l-norleucine derivative (xvi), which is cyclized by means of tetrabutylammonium fluoride and diea in hot acetonitrile giving the (2s)-piperidyl derivative (xvii). finally, this compound is hydrolyzed with lioh in thf/water to the labeled intermediate (ii).
List of intermediates No.
(1s,2s)-3-amino-1-(2-ethoxyphenoxy)-1-phenyl-2-propanol (ii)
isopropyl (3s,6r,7s,8s,12z,15s,16e)-15-(acetoxy)-7-(benzyloxy)-3-[[tert-butyl(dimethyl)silyl]oxy]-4,4,6,8,16-pentamethyl-17-(2-methyl-1,3-thiazol-4-yl)-5-oxo-12,16-heptadecadienoate (xii)
(3s,6r,7s,8s,12z,15s,16e)-7-(benzyloxy)-3-[[tert-butyl(dimethyl)silyl]oxy]-15-hydroxy-4,4,6,8,16-pentamethyl-17-(2-methyl-1,3-thiazol-4-yl)-5-oxo-12,16-heptadecadienoic acid (xiii)
(4s,7r,8s,9s,16s)-8-(benzyloxy)-4-[[tert-butyl(dimethyl)silyl]oxy]-5,5,7,9-tetramethyl-16-[(e)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]oxa-13-cyclohexadecene-2,6-dione (xiv)
3-(benzyloxy)-2,2-dimethylpropanal (xv)
(e)-7-(benzyloxy)-6,6-dimethyl-4-hepten-3-one (xvi)
1-[3-[2-(benzyloxy)-1,1-dimethylethyl]-2-oxiranyl]-1-propanone (xvii)
1-[3-[2-(benzyloxy)-1,1-dimethylethyl]-2-oxiranyl]-1-propanone o-methyloxime (xi)
{(2r,4s,5r)-4-(acetyloxy)-3-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl 2-(acetyloxy)-2-methylpropanoate (ii)
1-(tert-butyl) 3-methyl 3,6-dihydro-1,3(2h)-pyridinedicarboxylate (xiii)
tert-butyl 3-(hydroxymethyl)-3,6-dihydro-1(2h)-pyridinecarboxylate (xv)
tert-butyl 5-(hydroxymethyl)-7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate (xvi)
(3s,4r,5s)-3-(hydroxymethyl)-5-methyl-4-piperidinol (xvii)
(3r,4r,5r)-5-(hydroxymethyl)-3,4-piperidinediol (xi)
Reference 1:
    moenius, t.; et al.; c-14 labelling of nvp rad001 - a new rapamycin derivative. j label compd radiopharm 1999, 42, 1, 29.

来源:药化网

作者:药化小编

摘要:本文合成路线介绍的是药物中文名依维莫司;英文名Everolimus;RAD-001;NVP-RAD-001;SDZ-RAD;Certican;CAS[159351-69-6]

 
推荐VIP企业
无锡景耀生物科技有限公司
杭州卢普生物科技有限公司
宁波赛伦化工有限公司
苏州昊赛生物科技有限公司
北京嘉盛扬医药科技有限公司
上海泽涵生物医药科技有限公司
河北固安三利化工公司
郑州凯普瑞生物技术有限公司
上海药谷药业有限公司
兰州康寓信生物科技有限公司
湖北朗昕生化药业有限公司
武汉福鑫化工有限公司
嘉兴市英南化工有限公司
苏州迪飞医药科技有限公司
唐山盛源泽兴化工有限公司
上海盛中医药化工有限公司
连云港天和化学有限公司
南京晨瑞医药科技有限公司
南京苏如化工有限公司
常州瑞盛化工有限公司
热门文章
卢森堡将自2021年起禁止草甘
我国自主开发的首个植物生长调节
2019年中国农业科学10大重
回顾中国农药发展历程,思考行业
巴斯夫:到2030年在巴西推出
辉丰股份拟申请市级复产复核,原
浅析2019年农药登记情况及未
国内最大二甲戊灵原药生产企业—
诺普信战略投资云南华云金鑫,聚
UPL拟收购乐亭永乐100%股
销售额超5亿美元的最年轻品种,
17种铜制剂在我国的登记作物范
“ST丰山”变更为“丰山集团”
第十二届Agrow Award
国家农业最新补贴政策,不要错过
极具潜力的除草剂——吡氟酰草胺
国内乳腺癌潜力市场,第2款CD
走专精特新之路,打造隐形冠军—
苏利股份氟啶胺原药获得巴西登记
国务院:原研药/一致性仿制药,
 友情链接
有机化学人才网  
首页 | 广告服务 | 建站服务 | 关于我们 | 联系我们 | 版权声明